Top

Published in:

01-06-2020 | Benign Prostatic Hypertrophy | Urology - Review

Meta-analysis and systematic review of intermediate-term follow-up of prostatic urethral lift for benign prostatic hyperplasia

Authors: Karthik Tanneru, Shiva Gautam, Daniel Norez, Jatinder Kumar, Muhammad Umar Alam, Shahriar Koocheckpour, K. C. Balaji, Costa Joseph

Published in: International Urology and Nephrology | Issue 6/2020

Abstract

Background

Prostatic urethral lift (PUL), is a relatively new minimally invasive procedure for treatment of benign prostatic hyperplasia (BPH).This article is a systematic review and meta-analysis of all the articles published including follow-up of at least 24 months to analyze sustainability of results.

Methods

We performed a critical review in according to the preferred reporting items for systematic review and meta-analysis (PRISMA) guidelines. From a total 768 published articles that matched our search terms, 5 studies with minimum follow-up of 24 months were selected for comparison and data analyzed in terms of baseline characteristics, functional, and sexual health outcomes.

Results

Included in the analyses are five studies with a minimum follow-up of 24 months. A total of 386 patients underwent PUL and 322 patients (83.4%) are available for follow-up at 24 months. The randomized studies are grouped as group A and non-randomized studies as group B. At 24 months, the mean reduction in International Prostate Symptom Score (IPSS) from baseline was 9.1 in group A and 10.4 in group B. The mean improvement in peak flow rate (Q_max) was 3.7 mL/s in group A and 3 mL/s in group B, and quality of life (QoL) improved by 2.2 in both groups.

Conclusion

PUL is a well-tolerated, minimally invasive therapy for BPH that provides favorable and durable symptomatic, sexual health, and functional outcomes up to 24 months. Longer follow-up and randomized studies comparing to current standards are required to further confirm the long-term sustainability of PUL.

Available only for authorised users

St Sauver JL, Jacobson DJ, Girman CJ, Lieber MM, McGree ME, Jacobsen SJ (2006) Tracking of longitudinal changes in measures of benign prostatic hyperplasia in a population based cohort. J Urol 175(3 Pt 1):1018–1022. https://doi.org/10.1016/s0022-5347(05)00408-8(discussion 980) CrossRefPubMed

Ally M, Lee T, Ecclestone H, Teo L, Kavia R (2017) Malignant features of a benign waiting list. J Clin Urol 10(2):105–109CrossRef

Roehrborn CG (2011) Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin 95(1):87–100

Verhamme KM, Dieleman JP, Bleumink GS, Bosch JL, Stricker BH, Sturkenboom MC (2003) Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project. Eur Urol 44(5):539–545. https://doi.org/10.1016/s0302-2838(03)00376-2 CrossRefPubMed

Rassweiler J, Teber D, Kuntz R, Hofmann R (2006) Complications of transurethral resection of the prostate (TURP)–incidence, management, and prevention. Eur Urol 50(5):969–979. https://doi.org/10.1016/j.eururo.2005.12.042(discussion 980) CrossRefPubMed

Magistro G, Chapple CR, Elhilali M, Gilling P, McVary KT, Roehrborn CG, Stief CG, Woo HH, Gratzke C (2017) Emerging minimally invasive treatment options for male lower urinary tract symptoms. Eur Urol 72(6):986–997. https://doi.org/10.1016/j.eururo.2017.07.005 CrossRefPubMed

Jones P, Rajkumar GN, Rai BP, Aboumarzouk OM, Cleaveland P, Srirangam SJ, Somani BK (2016) Medium-term outcomes of urolift (Minimum 12 Months Follow-up): evidence from a systematic review. Urology 97:20–24. https://doi.org/10.1016/j.urology.2016.05.003 CrossRefPubMed

Magistro G, Stief CG, Woo HH (2018) Mini-review: what is new in urolift? Eur Urol Focus 4(1):36–39. https://doi.org/10.1016/j.euf.2018.01.013 CrossRefPubMed

Woo HH, Chin PT, McNicholas TA, Gill HS, Plante MK, Bruskewitz RC, Roehrborn CG (2011) Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int 108(1):82–88. https://doi.org/10.1111/j.1464-410X.2011.10342.x CrossRefPubMed

10.

Chin PT, Bolton DM, Jack G, Rashid P, Thavaseelan J, Yu RJ, Roehrborn CG, Woo HH (2012) Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 79(1):5–11. https://doi.org/10.1016/j.urology.2011.10.021 CrossRefPubMed

11.

McNicholas TA, Woo HH, Chin PT, Bolton D, Fernandez Arjona M, Sievert KD, Schoenthaler M, Wetterauer U, Vrijhof EJ, Gange S, Montorsi F (2013) Minimally invasive prostatic urethral lift: surgical technique and multinational experience. Eur Urol 64(2):292–299. https://doi.org/10.1016/j.eururo.2013.01.008 CrossRefPubMed

12.

Roehrborn CG, Rukstalis DB, Barkin J, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, Cantwell AL, McVary KT, Te AE, Gholami SS, Moseley WG, Chin PT, Dowling WT, Freedman SJ, Incze PF, Coffield KS, Borges FD, Rashid P (2015) Three year results of the prostatic urethral LIFT study. Can J Urol 22(3):7772–7782PubMed

13.

Roehrborn CG, Barkin J, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, Cantwell AL, McVary KT, Te AE, Gholami SS, Moseley WG, Chin PT, Dowling WT, Freedman SJ, Incze PF, Coffield KS, Herron S, Rashid P, Rukstalis DB (2017) Five year results of the prospective randomized controlled prostatic urethral LIFT study. Can J Urol 24(3):8802–8813PubMed

14.

Cantwell AL, Bogache WK, Richardson SF, Tutrone RF, Barkin J, Fagelson JE, Chin PT, Woo HH (2014) Multicentre prospective crossover study of the 'prostatic urethral lift' for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. BJU Int 113(4):615–622. https://doi.org/10.1111/bju.12540 CrossRefPubMed

15.

Sonksen J, Barber NJ, Speakman MJ, Berges R, Wetterauer U, Greene D, Sievert KD, Chapple CR, Montorsi F, Patterson JM, Fahrenkrug L, Schoenthaler M, Gratzke C (2015) Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. Eur Urol 68(4):643–652. https://doi.org/10.1016/j.eururo.2015.04.024 CrossRefPubMed

16.

Bozkurt A, Karabakan M, Keskin E, Hirik E, Balci MB, Nuhoglu B (2016) Prostatic urethral lift: a new minimally invasive treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urol Int 96(2):202–206. https://doi.org/10.1159/000441850 CrossRefPubMed

17.

Gratzke C, Barber N, Speakman MJ, Berges R, Wetterauer U, Greene D, Sievert KD, Chapple CR, Patterson JM, Fahrenkrug L, Schoenthaler M, Sonksen J (2017) Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study. BJU Int 119(5):767–775. https://doi.org/10.1111/bju.13714 CrossRefPubMed

18.

Rukstalis D, Rashid P, Bogache WK, Tutrone RF, Barkin J, Chin PT, Woo HH, Cantwell AL, Cowan BE, Bolton DM (2016) 24-month durability after crossover to the prostatic urethral lift from randomised, blinded sham. BJU Int 118(Suppl 3):14–22. https://doi.org/10.1111/bju.13666 CrossRefPubMed

19.

Shah BB, Tayon K, Madiraju S, Carrion RE, Perito P (2018) Prostatic urethral lift: does size matter? J Endourol 32(7):635–638. https://doi.org/10.1089/end.2017.0855 CrossRefPubMed

20.

Sievert KD, Schonthaler M, Berges R, Toomey P, Drager D, Herlemann A, Miller F, Wetterauer U, Volkmer B, Gratzke C, Amend B (2019) Minimally invasive prostatic urethral lift (PUL) efficacious in TURP candidates: a multicenter German evaluation after 2 years. World J Urol 37(7):1353–1360. https://doi.org/10.1007/s00345-018-2494-1 CrossRefPubMed

21.

Garcia C, Chin P, Rashid P, Woo HH (2015) Prostatic urethral lift: a minimally invasive treatment for benign prostatic hyperplasia. Prostate Int 3(1):1–5. https://doi.org/10.1016/j.prnil.2015.02.002 CrossRefPubMedPubMedCentral

22.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6(7):e1000100. https://doi.org/10.1371/journal.pmed.1000100 CrossRefPubMedPubMedCentral

23.

Deeks JJ, Higgins JP, Altman DG (2008) Analysing data and undertaking meta‐analyses. Cochrane Handb Syst Rev Interv, pp 241–284

24.

Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT (1992) The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148(5):1549–1557. https://doi.org/10.1016/s0022-5347(17)36966-5(discussion 1564) CrossRefPubMed

25.

Rosen RC, Catania J, Pollack L, Althof S, O'Leary M, Seftel AD (2004) Male Sexual Health Questionnaire (MSHQ): scale development and psychometric validation. Urology 64(4):777–782. https://doi.org/10.1016/j.urology.2004.04.056 CrossRefPubMed

26.

Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM et al. (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898 https://doi.org/10.1136/bmj.l4898 CrossRefPubMed

27.

Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:4919CrossRef

28.

McGuinness LA (2019) Robvis: an R package and web application for visualising risk-of-bias assessments. https://github.com/mcguinlu/robvis

29.

von Hippel PT (2015) The heterogeneity statistic I(2) can be biased in small meta-analyses. BMC Med Res Methodol 15:35. https://doi.org/10.1186/s12874-015-0024-z CrossRef

30.

Strope SA, Vetter J, Elliott S, Andriole GL, Olsen MA (2015) Use of medical therapy and success of laser surgery and transurethral resection of the prostate for benign prostatic hyperplasia. Urology 86(6):1115–1122. https://doi.org/10.1016/j.urology.2015.07.019 CrossRefPubMed

31.

Bouza C, Lopez T, Magro A, Navalpotro L, Amate JM (2006) Systematic review and meta-analysis of transurethral needle ablation in symptomatic benign prostatic hyperplasia. BMC Urol 6:14. https://doi.org/10.1186/1471-2490-6-14 CrossRefPubMedPubMedCentral

32.

Hoffman RM, Monga M, Elliott SP, Macdonald R, Langsjoen J, Tacklind J, Wilt TJ (2012) Microwave thermotherapy for benign prostatic hyperplasia. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD004135.pub3 CrossRefPubMed

33.

Eure G, Gange S, Walter P, Khan A, Chabert C, Mueller T, Cozzi P, Patel M, Freedman S, Chin P, Ochs S, Hirsh A, Trotter M, Grier D (2019) Real-world evidence of prostatic urethral lift confirms pivotal clinical study results: 2-year outcomes of a retrospective multicenter study. J Endourol 33(7):576–584. https://doi.org/10.1089/end.2019.0167 CrossRefPubMedPubMedCentral

34.

Jung JH, Reddy B, McCutcheon KA, Borofsky M, Narayan V, Kim MH, Dahm P (2019) Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database Syst Rev 5:Cd012832. https://doi.org/10.1002/14651858.CD012832.pub2 CrossRefPubMed

35.

US Department of Health and Human Services CfMaMSPBNSDF (2016) https://www.cms.gov/Research-Statistics-Data-and-Systems/Downloadable-Public-Use-Files/Part-B-National-Summary-Data-File/Overview.html.

Title: Meta-analysis and systematic review of intermediate-term follow-up of prostatic urethral lift for benign prostatic hyperplasia
Authors: Karthik Tanneru
Shiva Gautam
Daniel Norez
Jatinder Kumar
Muhammad Umar Alam
Shahriar Koocheckpour
K. C. Balaji
Costa Joseph
Publication date: 01-06-2020
Publisher: Springer Netherlands
Keywords: Benign Prostatic Hypertrophy
Benign Prostatic Hypertrophy
Transurethral Prostate Resection
Published in: International Urology and Nephrology / Issue 6/2020
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-020-02408-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2020

Do rapid emotional thermometers correlate with multidimensional validated structured questionnaires in low-risk prostate cancer?

The impact of donor urine chemical toxicology analysis on outcomes of kidney transplantation

Risk calculator for prediction of treatment-related urethroplasty failure in patients with penile urethral strictures

COVID-19 research: promising tracks leading to uro-oncology

The theoretical method and clinical application of testicular torsion

Risk factors for decreased upper-limb muscle strength and its impact on survival in maintenance hemodialysis patients

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials